Table 3.
Genes, no. (%) | North America n = 26 (23) | Europe & Middle East n = 76 (68) | Australia & New Zealand n = 10 (9) | P value |
Adhesins | ||||
fnbA | 26 (100) | 76 (100.0) | 8 (80) | .007a |
fnbB | 8 (30.8) | 5 (6.8) | 2 (20) | .006a |
clfA | 26 (100) | 75 (98.7) | 10 (100) | 1.000 |
clfB | 26 (100) | 76 (100.0) | 10 (100) | … |
cna | 18 (69.2) | 67 (88.2) | 7 (70) | .041 |
spa | 24 (92.3) | 75 (98.7) | 10 (100) | .241 |
sdrC | 14 (53.8) | 33 (43.4) | 3 (30) | .385 |
sdrD | 17 (65.4) | 45 (59.2) | 8 (80) | .450 |
sdrE | 15 (57.7) | 37 (48.7) | 7 (70) | .389 |
bbp | 24 (92.3) | 67 (88.2) | 8 (80) | .516 |
ebpS | 26 (100.0) | 76 (100.0) | 10 (100.0) | … |
map/eap | 15 (57.7) | 40 (52.6) | 8 (80) | .290 |
Toxins | ||||
eta | 8 (30.8) | 17 (22.4) | 2 (20) | .683 |
etb | 0 (0.0) | 5 (6.6) | 0 (0) | .581 |
tst | 23 (88.5) | 73 (96.1) | 9 (90) | .217 |
sea | 16 (61.5) | 50 (65.8) | 6 (60) | .860 |
seb | 2 (7.7) | 0 (0.0) | 2 (20) | .004a |
sec | 9 (34.6) | 16 (21.1) | 4 (40) | .224 |
sed | 9 (34.6) | 12 (15.8) | 3 (30) | .098 |
see | 0 (0.0) | 28 (36.8) | 3 (30) | <.001a |
seg | 16 (61.5) | 57 (75) | 5 (50) | .163 |
seh | 4 (15.4) | 8 (10.5) | 1 (10) | .800 |
sei | 24 (92.3) | 66 (86.8) | 10 (100) | .626 |
sej | 2 (7.7) | 1 (1.3) | 1 (10) | .118 |
pvl | 0 (0.0) | 20 (26.3) | 1 (10) | .003a |
hlg | 26 (100) | 76 (100) | 10 (100) | … |
Other putative virulence genes | ||||
efb | 26 (100) | 75 (98.7) | 10 (100) | 1.000 |
icaA | 26 (100) | 68 (89.5) | 10 (100) | .182 |
chp | 24 (92.3) | 61 (80.3) | 7 (70) | .213 |
v8 | 17 (65.4) | 40 (52.6) | 8 (80) | .211 |
AGR group | ||||
agr I | 8 (30.8) | 24 (31.6) | 4 (40) | .894 |
agr II | 9 (34.6) | 26 (34.2) | 4 (40) | … |
Agr III | 9 (34.6) | 21 (27.6) | 2 (20) | … |
Agr IV | 0 (0.0) | 5 (6.6) | 0 (0) | … |
NOTE. Two of 114 patients were excluded from geographical analysis because they originated from South America.
Statistically significant after adjustment for multiple comparisons using a false discovery rate of 10%.